EquitySector - HealthcareVery High Risk
Regular
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹4,915 Cr
Expense Ratio
1.94%
ISIN
INF109KC1GE9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
12 Jul 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+20.01%
+17.55% (Cat Avg.)
3 Years
+22.38%
+18.10% (Cat Avg.)
5 Years
+25.42%
+22.46% (Cat Avg.)
Since Inception
+21.11%
— (Cat Avg.)
Equity | ₹4,830.34 Cr | 98.28% |
Others | ₹84.3 Cr | 1.72% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹663.39 Cr | 13.50% |
Dr Reddy's Laboratories Ltd | Equity | ₹439.66 Cr | 8.95% |
Cipla Ltd | Equity | ₹434.83 Cr | 8.85% |
Divi's Laboratories Ltd | Equity | ₹329.56 Cr | 6.71% |
Aurobindo Pharma Ltd | Equity | ₹260.52 Cr | 5.30% |
Lupin Ltd | Equity | ₹232.32 Cr | 4.73% |
Alkem Laboratories Ltd | Equity | ₹217.44 Cr | 4.42% |
Mankind Pharma Ltd | Equity | ₹171.92 Cr | 3.50% |
Gland Pharma Ltd | Equity | ₹166.43 Cr | 3.39% |
Zydus Lifesciences Ltd | Equity | ₹152.37 Cr | 3.10% |
Apollo Hospitals Enterprise Ltd | Equity | ₹138.58 Cr | 2.82% |
Syngene International Ltd | Equity | ₹103.55 Cr | 2.11% |
Atul Ltd | Equity | ₹94.93 Cr | 1.93% |
Windlas Biotech Ltd | Equity | ₹89.24 Cr | 1.82% |
Pfizer Ltd | Equity | ₹86.99 Cr | 1.77% |
Alembic Pharmaceuticals Ltd | Equity | ₹80.97 Cr | 1.65% |
Medplus Health Services Ltd | Equity | ₹75.77 Cr | 1.54% |
SBI Life Insurance Co Ltd | Equity | ₹72.65 Cr | 1.48% |
Biocon Ltd | Equity | ₹70.97 Cr | 1.44% |
Advanced Enzyme Technologies Ltd | Equity | ₹70.3 Cr | 1.43% |
Treps | Cash - Repurchase Agreement | ₹69.12 Cr | 1.41% |
Medi Assist Healthcare Services Ltd | Equity | ₹66.55 Cr | 1.35% |
Shilpa Medicare Ltd | Equity | ₹63.9 Cr | 1.30% |
Fine Organic Industries Ltd Ordinary Shares | Equity | ₹60.2 Cr | 1.22% |
Glenmark Pharmaceuticals Ltd | Equity | ₹58.38 Cr | 1.19% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹51.74 Cr | 1.05% |
AstraZeneca Pharma India Ltd | Equity | ₹51.66 Cr | 1.05% |
Aarti Industries Ltd | Equity | ₹51.55 Cr | 1.05% |
Thyrocare Technologies Ltd | Equity | ₹50.91 Cr | 1.04% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹49.35 Cr | 1.00% |
Aarti Drugs Ltd | Equity | ₹47.25 Cr | 0.96% |
FDC Ltd | Equity | ₹47.18 Cr | 0.96% |
Sun Pharma Advanced Research Co Ltd | Equity | ₹42.57 Cr | 0.87% |
Procter & Gamble Health Ltd | Equity | ₹40.15 Cr | 0.82% |
Max Financial Services Ltd | Equity | ₹38.7 Cr | 0.79% |
Senores Pharmaceuticals Ltd | Equity | ₹36.57 Cr | 0.74% |
Star Health and Allied Insurance Co Ltd | Equity | ₹32.26 Cr | 0.66% |
Emcure Pharmaceuticals Ltd | Equity | ₹31.92 Cr | 0.65% |
Unichem Laboratories Ltd | Equity | ₹17.15 Cr | 0.35% |
Alivus Life Sciences Ltd | Equity | ₹13.86 Cr | 0.28% |
Laxmi Organic Industries Ltd | Equity | ₹11.88 Cr | 0.24% |
Laxmi Dental Ltd | Equity | ₹9.26 Cr | 0.19% |
Cash Margin - Derivatives | Cash - Collateral | ₹8.41 Cr | 0.17% |
Net Current Assets | Cash | ₹6.78 Cr | 0.14% |
Galaxy Surfactants Ltd | Equity | ₹4.96 Cr | 0.10% |
Large Cap Stocks
42.58%
Mid Cap Stocks
26.30%
Small Cap Stocks
29.22%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹4,392.91 Cr | 89.38% |
Basic Materials | ₹293.82 Cr | 5.98% |
Financial Services | ₹143.62 Cr | 2.92% |
Standard Deviation
This fund
16.24%
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
0.95
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since May 2020
Since July 2022
ISIN INF109KC1GE9 | Expense Ratio 1.94% | Exit Load 1.00% | Fund Size ₹4,915 Cr | Age 6 years 9 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹8,67,406 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Regular
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹4,915 Cr
Expense Ratio
1.94%
ISIN
INF109KC1GE9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
12 Jul 2018
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+20.01%
+17.55% (Cat Avg.)
3 Years
+22.38%
+18.10% (Cat Avg.)
5 Years
+25.42%
+22.46% (Cat Avg.)
Since Inception
+21.11%
— (Cat Avg.)
Equity | ₹4,830.34 Cr | 98.28% |
Others | ₹84.3 Cr | 1.72% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹663.39 Cr | 13.50% |
Dr Reddy's Laboratories Ltd | Equity | ₹439.66 Cr | 8.95% |
Cipla Ltd | Equity | ₹434.83 Cr | 8.85% |
Divi's Laboratories Ltd | Equity | ₹329.56 Cr | 6.71% |
Aurobindo Pharma Ltd | Equity | ₹260.52 Cr | 5.30% |
Lupin Ltd | Equity | ₹232.32 Cr | 4.73% |
Alkem Laboratories Ltd | Equity | ₹217.44 Cr | 4.42% |
Mankind Pharma Ltd | Equity | ₹171.92 Cr | 3.50% |
Gland Pharma Ltd | Equity | ₹166.43 Cr | 3.39% |
Zydus Lifesciences Ltd | Equity | ₹152.37 Cr | 3.10% |
Apollo Hospitals Enterprise Ltd | Equity | ₹138.58 Cr | 2.82% |
Syngene International Ltd | Equity | ₹103.55 Cr | 2.11% |
Atul Ltd | Equity | ₹94.93 Cr | 1.93% |
Windlas Biotech Ltd | Equity | ₹89.24 Cr | 1.82% |
Pfizer Ltd | Equity | ₹86.99 Cr | 1.77% |
Alembic Pharmaceuticals Ltd | Equity | ₹80.97 Cr | 1.65% |
Medplus Health Services Ltd | Equity | ₹75.77 Cr | 1.54% |
SBI Life Insurance Co Ltd | Equity | ₹72.65 Cr | 1.48% |
Biocon Ltd | Equity | ₹70.97 Cr | 1.44% |
Advanced Enzyme Technologies Ltd | Equity | ₹70.3 Cr | 1.43% |
Treps | Cash - Repurchase Agreement | ₹69.12 Cr | 1.41% |
Medi Assist Healthcare Services Ltd | Equity | ₹66.55 Cr | 1.35% |
Shilpa Medicare Ltd | Equity | ₹63.9 Cr | 1.30% |
Fine Organic Industries Ltd Ordinary Shares | Equity | ₹60.2 Cr | 1.22% |
Glenmark Pharmaceuticals Ltd | Equity | ₹58.38 Cr | 1.19% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹51.74 Cr | 1.05% |
AstraZeneca Pharma India Ltd | Equity | ₹51.66 Cr | 1.05% |
Aarti Industries Ltd | Equity | ₹51.55 Cr | 1.05% |
Thyrocare Technologies Ltd | Equity | ₹50.91 Cr | 1.04% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹49.35 Cr | 1.00% |
Aarti Drugs Ltd | Equity | ₹47.25 Cr | 0.96% |
FDC Ltd | Equity | ₹47.18 Cr | 0.96% |
Sun Pharma Advanced Research Co Ltd | Equity | ₹42.57 Cr | 0.87% |
Procter & Gamble Health Ltd | Equity | ₹40.15 Cr | 0.82% |
Max Financial Services Ltd | Equity | ₹38.7 Cr | 0.79% |
Senores Pharmaceuticals Ltd | Equity | ₹36.57 Cr | 0.74% |
Star Health and Allied Insurance Co Ltd | Equity | ₹32.26 Cr | 0.66% |
Emcure Pharmaceuticals Ltd | Equity | ₹31.92 Cr | 0.65% |
Unichem Laboratories Ltd | Equity | ₹17.15 Cr | 0.35% |
Alivus Life Sciences Ltd | Equity | ₹13.86 Cr | 0.28% |
Laxmi Organic Industries Ltd | Equity | ₹11.88 Cr | 0.24% |
Laxmi Dental Ltd | Equity | ₹9.26 Cr | 0.19% |
Cash Margin - Derivatives | Cash - Collateral | ₹8.41 Cr | 0.17% |
Net Current Assets | Cash | ₹6.78 Cr | 0.14% |
Galaxy Surfactants Ltd | Equity | ₹4.96 Cr | 0.10% |
Large Cap Stocks
42.58%
Mid Cap Stocks
26.30%
Small Cap Stocks
29.22%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹4,392.91 Cr | 89.38% |
Basic Materials | ₹293.82 Cr | 5.98% |
Financial Services | ₹143.62 Cr | 2.92% |
Standard Deviation
This fund
16.24%
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
0.95
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since May 2020
Since July 2022
ISIN INF109KC1GE9 | Expense Ratio 1.94% | Exit Load 1.00% | Fund Size ₹4,915 Cr | Age 6 years 9 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹8,67,406 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments